optum ses database (Optum Inc)
86
Structured Review
Optum Inc
optum ses database
Optum Ses Database, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum+ses/database+optum+ses/pmc13157083-160-1-1
Average 86 stars, based on 1 article reviews
Optum Ses Database, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum+ses/database+optum+ses/pmc13157083-160-1-1
Average 86 stars, based on 1 article reviews
optum ses database - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
other:Article Title: Methods of treating multiple sclerosis Article Snippet: Similar results were obtained in the IBM MDCR and Article Title: The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases Article Snippet: Our study estimated the prevalence of Article Title: CohortDiagnostics: Phenotype evaluation across a network of observational data sources using population-level characterization. Article Snippet: We included 6 claims based data; JMDC, MerativeTM MarketScan1 Commercial Claims and Encounters Database (CCAE), MerativeTM MarketScan1Medicare Supplemental and Coordination of Benefits Database (MDCR), MerativeTM MarketScan1 Multi-State Medicaid Database (MDCD), IQVIA1 Adjudicated Health Plan Claims Data (Pharmetrics Plus), Optum’s Article Title: Disparities in adoption of new diabetic therapies with cardiovascular benefits. Article Snippet: Aims: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 agonists (GLP1a) have cardiovascular benefit, but adoption into clinical practice has been lagging.. We aim to evaluate use of SGLT2i and GLP1a across socioeconomic strata (SES), medical risk as well as provider type.. Methods: We conducted a retrospective cohort study of the prescription of SGLT2i or GLP1a within 12 months of clinic visit between January 1, 2018 and January 1, 2019 using de-identified claims data. Article Title: The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases. Article Snippet: Article Title: CohortDiagnostics: Phenotype evaluation across a network of observational data sources using population-level characterization Article Snippet: Article Title: Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals Article Snippet: Patient-level data from |